GIST-IMPACT
20.6.2024 08:01:35 CEST | Business Wire | Press release
Today GIST Impact, the leading provider of impact data and analytics, announced an investment from UBS Next, the leading universal Swiss bank’s venture and innovation unit.
GIST Impact delivers actionable impact intelligence to companies and investors, helping them easily measure their environmental and social impacts. The firm’s data and software are founded on a science-based, location-specific and standards-aligned approach, drawing on over 16 years of experience measuring and valuing impact. Its clients include some of the world’s largest banks, sovereign wealth funds, and technology firms.
The provision of better impact data is critical in developing greater transparency for investors to help them manage their portfolios. New regulations and standards have also set a higher bar for measuring impact across value chains - whether through assessing impact materiality as part of the Corporate Sustainability Reporting Directive (CSRD) or evaluating natural capital impact as part of the Taskforce on Nature-related Financial Disclosures (TNFD).
The investment from UBS Next will support the further expansion of GIST Impact’s product integrations with partners and development of proprietary impact data and software solutions, including preparations for CSRD and TNFD requirements where clients require most support.
Andre Hoffmann, Co-Founder of GIST Impact, said, “This partnership with UBS marks a pivotal moment for GIST Impact as we set new standards for how companies and investors can integrate environmental and social considerations into their core business strategies. Our collaboration is more than an investment; it's a shared commitment to foster a more sustainable future where financial success is inextricably linked to positive impact on the planet and society. We are thrilled to join forces with UBS to drive this change forward, ensuring that our clients are not just prepared for the future but are actively shaping it."
“We believe that actionable impact intelligence and data will help investors manage their portfolios in a targeted manner and match opportunities and environmental and social impact. This is a pre-requisite to create long-term sustainable outcomes,” said Sergio Ermotti, Group CEO of UBS.
“We’re proud to partner with UBS to accelerate this next stage in our growth. Our world-leading impact data and intelligence algorithms empower investors to manage their portfolios towards better social and environmental outcomes and impacts,” said Pavan Sukhdev, Co-Founder and CEO of GIST Impact. “Furthermore, our impact valuation platforms help companies evaluate their impacts, dependencies, risks and opportunities, helping create long-term sustainable value.”
About GIST Impact
GIST Impact is a market-leading impact data and analytics provider, measuring, quantifying and valuing corporate impacts on society and the environment for over 16 years. With a team of 120+ data scientists, engineers, ecologists and economists, GIST Impact delivers location-specific impact data covering 14,500+ companies. Since 2021, the firm has automated its systems to provide investment portfolio impacts, and its clients include investors representing over $8 trillion in assets under management as well as leading global corporations. GIST Impact also partners with some of the largest consulting firms, business networks, and fintech platforms to enable impact measurement and reporting across global markets.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240619424763/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE03428.2.2026 01:00:00 CET | Press release
IDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to target tumor cells expressing both B7H3 and PTK7 preferentially, and is being evaluated as monotherapy and in combination with IDEAYA’s PARG inhibitor IDE161. IDEAYA has dosed the first patient in its Phase 1 trial of IDE034, initially evaluating safety, tolerability, and PK. First dosing triggers a $5 million milestone payment to Biocytogen under the companies’ option and license agreement. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million
IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 13:00:00 CET | Press release
IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p
HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 12:00:00 CET | Press release
HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP)Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 ConstraintsNot Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. Cha
Kioxia Appoints Yoshihiko Kawamura as Chief Financial Officer27.2.2026 09:15:00 CET | Press release
Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced the appointment of Yoshihiko Kawamura as Chief Financial Officer (CFO), effective April 1, 2026. Mr. Kawamura brings extensive international experience to Kioxia, having held assignments at Mitsubishi Corporation’s U.S. headquarters, served as General Manager of its Chicago office, and completed a tenure at the World Bank. At Hitachi, Ltd., he held senior leadership positions, including Chief Strategy Officer (CSO), Chief Financial Officer (CFO), and Chief Risk Management Officer (CRMO), where he was instrumental in leading the company’s management reforms. Since joining Kioxia as Executive Vice President in June 2025, Mr. Kawamura has worked closely with the executive team to advance the business through strategic capital and financial planning. Following its initial public offering on the Prime Market of the Tokyo Stock Exchange in December 2024, Kioxia is entering a new phase of growth char
DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 08:18:00 CET | Press release
Will accelerate the development and mass production of EUV lithography photomasks Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom